Contribution of histidine-rich glycoprotein in clearance of immune complexes and apoptotic cells: Implications for ameliorating autoimmune diseases

References

• Jones AL, Hulett MD, Parish CR. Histidine-rich glycoprotein: A novel adaptor protein in plasma that modulates the immune, vascular and coagulation systems. Immunol Cell Biol 2005; 83(2)106–118
   PubMed Web of Science ®Google Scholar
• Nair PS, Robinson WE. Purification and characterization of a histidine-rich glycoprotein that binds cadmium from the blood plasma of the bivalve Mytilus edulis. Arch Biochem Biophys 1999; 366(1)8–14
   PubMedGoogle Scholar
• Lijnen HR, DeCock F, Collen D. Turnover of human histidine-rich glycoprotein in healthy subjects and during thrombolytic therapy. Thromb Res 1981; 23(1–2)121–131
   PubMedGoogle Scholar
• Leung LL, Harpel PC, Nachman RL, Rabellino EM. Histidine-rich glycoprotein is present in human platelets and is released following thrombin stimulation. Blood 1983; 62(5)1016–1021
   PubMedGoogle Scholar
• Sia DY, Rylatt DB, Parish CR. Anti-self receptors. V. Properties of a mouse serum factor that blocks autorosetting receptors on lymphocytes. Immunology 1982; 45(2)207–216
   PubMedGoogle Scholar
• Koide T, Foster D, Odani S. The heparin-binding site(s) of histidine-rich glycoprotein as suggested by sequence homology with antithrombin III. FEBS Lett 1986; 194(2)242–244
   PubMedGoogle Scholar
• Koide T, Foster D, Yoshitake S, Davie EW. Amino acid sequence of human histidine-rich glycoprotein derived from the nucleotide sequence of its cDNA. Biochemistry 1986; 25(8)2220–2225
   PubMed Web of Science ®Google Scholar
• Kyte J, Doolittle RF. A simple method for displaying the hydropathic character of a protein. J Mol Biol 1982; 157(1)105–132
   PubMed Web of Science ®Google Scholar
• Sorensen CB, Krogh-Pedersen H, Petersen TE. Determination of the disulphide bridge arrangement of bovine histidine-rich glycoprotein. FEBS Lett 1993; 328(3)285–290
   PubMedGoogle Scholar
• Heimburger N, Haupt H, Kranz T, Baudner S. Human serum proteins with high affinity to carboxymethylcellulose II. Physico–chemical and immunological characterization of a histidine-rich 3,8S- 2 -glycoportein (CM-protein I). Hoppe Seylers Z Physiol Chem 1972; 353(7)1133–1140
   PubMedGoogle Scholar
• Borza DB, Tatum FM, Morgan WT. Domain structure and conformation of histidine-proline-rich glycoprotein. Biochemistry 1996; 35(6)1925–1934
   PubMed Web of Science ®Google Scholar
• Morgan WT. The histidine-rich glycoprotein of serum has a domain rich in histidine, proline, and glycine that binds heme and metals. Biochemistry 1985; 24(6)1496–1501
   PubMed Web of Science ®Google Scholar
• Brown KJ, Parish CR. Histidine-rich glycoprotein and platelet factor 4 mask heparan sulfate proteoglycans recognized by acidic and basic fibroblast growth factor. Biochemistry 1994; 33(46)13918–13927
   PubMedGoogle Scholar
• Silverstein RL, Leung LL, Harpel PC, Nachman RL. Platelet thrombospondin forms a trimolecular complex with plasminogen and histidine-rich glycoprotein. J Clin Invest 1985; 75(6)2065–2073
   PubMed Web of Science ®Google Scholar
• Leung LL. Interaction of histidine-rich glycoprotein with fibrinogen and fibrin. J Clin Invest 1986; 77(4)1305–1311
   PubMed Web of Science ®Google Scholar
• Borza DB, Morgan WT. Acceleration of plasminogen activation by tissue plasminogen activator on surface-bound histidine-proline-rich glycoprotein. J Biol Chem 1997; 272(9)5718–5726
   PubMedGoogle Scholar
• Chang NS, Leu RW, Rummage JA, Anderson JK, Mole JE. Regulation of complement functional efficiency by histidine-rich glycoprotein. Blood 1992; 79(11)2973–2980
   PubMedGoogle Scholar
• Gorgani NN, Parish CR, Easterbrook Smith SB, Altin JG. Histidine-rich glycoprotein binds to human IgG and C1q and inhibits the formation of insoluble immune complexes. Biochemistry 1997; 36(22)6653–6662
   PubMedGoogle Scholar
• Guan X, Juarez JC, Qi X, Shipulina NV, Shaw DE, Morgan WT, McCrae KR, Mazar AP, Donate F. Histidine-proline rich glycoprotein (HPRG) binds and transduces anti-angiogenic signals through cell surface tropomyosin on endothelial cells. Thromb Haemost 2004; 92(2)403–412
   PubMedGoogle Scholar
• Parish CR, Rylatt DB, Snowden JM. Demonstration of lymphocyte surface lectins that recognize sulphated polysaccharides. J Cell Sci 1984; 67: 145–158
   PubMed Web of Science ®Google Scholar
• Chang NS, Leu RW, Anderson JK, Mole JE. Role of N-terminal domain of histidine-rich glycoprotein in modulation of macrophage Fc gamma receptor-mediated phagocytosis. Immunology 1994; 81(2)296–302
   PubMedGoogle Scholar
• Saigo K, Shatsky M, Levitt LJ, Leung LK. Interaction of histidine-rich glycoprotein with human T lymphocytes. J Biol Chem 1989; 264(14)8249–8253
   PubMedGoogle Scholar
• Hennis BC, van Boheemen PA, Wakabayashi S, Koide T, Hoffmann JJ, Kievit P, Dooijewaard G, Jansen JG, Kluft C. Identification and genetic analysis of a common molecular variant of histidine-rich glycoprotein with a difference of 2 kD in apparent molecular weight. Thromb Haemost 1995; 74(6)1491–1496
   PubMedGoogle Scholar
• Morgan WT, Koskelo P, Koenig H, Conway TP. Human histidine-rich glycoprotein II. Serum levels in adults, pregnant women and neonates. Proc Soc Exp Biol Med 1978; 158(4)647–651
   PubMedGoogle Scholar
• Corrigan JJ, Jr., Jeter MA, Bruck D, Feinberg WM. Histidine-rich glycoprotein levels in children: The effect of age. Thromb Res 1990; 59(3)681–686
   PubMedGoogle Scholar
• Corrigan JJ, Jr., Jeter MA. Histidine-rich glycoprotein and plasminogen plasma levels in term and preterm newborns. Am J Dis Child 1990; 144(7)825–828
   PubMedGoogle Scholar
• Drasin T, Sahud M. Blood-type and age affect human plasma levels of histidine-rich glycoprotein in a large population. Thromb Res 1996; 84(3)179–188
   PubMedGoogle Scholar
• Saigo K, Yoshida A, Ryo R, Yamaguchi N, Leung LL. Histidine-rich glycoprotein as a negative acute phase reactant. Am J Hematol 1990; 34(2)149–150
   PubMedGoogle Scholar
• Saigo K, Yoshida A, Sugano W, Ryo R, Yamaguchi N. Histidine-rich glycoprotein in blood during inflammation, surgical operation or hemodialysis. Rinsho Ketsueki 1990; 31(12)1914–1919
   PubMedGoogle Scholar
• Castel M, Horellou MH, Conard J, Samama M. Immunochemical determination of histidine-rich glycoprotein in healthy subjects and in a clinical population, JF Davidson, F Bachmann, CA Bouvier, EKO Kruithof. Churchill Livingstone, Edinburgh 1983; 370–373, (Progress in fibrinolysis)
   Google Scholar
• Castaman G, Ruggeri M, Burei F, Rodeghiero F. High levels of histidine-rich glycoprotein and thrombotic diathesis. Report of two unrelated families. Thromb Res 1993; 69(3)297–305
   PubMedGoogle Scholar
• Angles-Cano E, Gris JC, Loyau S, Schved JF. Familial association of high levels of histidine-rich glycoprotein and plasminogen activator inhibitor-1 with venous thromboembolism. J Lab Clin Med 1993; 121(5)646–653
   PubMedGoogle Scholar
• Souto JC, Gari M, Falkon L, Fontcuberta J. A new case of hereditary histidine-rich glycoprotein deficiency with familial thrombophilia. Thromb Haemost 1996; 75(2)374–375
   PubMedGoogle Scholar
• Tsuchida-Straeten N, Ensslen S, Schafer C, Woltje M, Denecke B, Moser M, Graber S, Wakabayashi S, Koide T, Jahnen-Dechent W. Enhanced blood coagulation and fibrinolysis in mice lacking histidine-rich glycoprotein (HRG). J Thromb Haemost 2005; 3(5)865–872
   PubMedGoogle Scholar
• Abrass CK. Mechanisms of immune complex formation and deposition in renal structure. Immunological renal diseases, NG Neilson, WG Couser. Lippincott-Raven publishers, Philadelphia 1997; 291–307
   Google Scholar
• Abrass CK. Autologous immune complex nephritis in rats. Influence of modification of mononuclear phagocyte system function. Lab Invest 1984; 51(2)162–171
   PubMedGoogle Scholar
• Charlesworth JA, Endre ZH, Pussell BA, Yasmeen D, Peake PW. Complement behavior in infectious mononucleosis: Possible mechanisms for the prevention of immune complex injury. J Infect Dis 1982; 145(4)505–513
   PubMedGoogle Scholar
• Balint JP, Jr. Immune modulation associated with extracorporeal immunoadsorption treatments utilizing protein A/silica columns. Artif Organs 1996; 20(8)906–913
   PubMedGoogle Scholar
• Gorgani NN, Easterbrook-Smith SB, Altin JG. The formation of insoluble immune complexes between ovalbumin and anti-ovalbumin IgG occurs in at least two distinct phases dependent on reactant concentration and ionic strength. Biochim Biophys Acta 1996; 1317(1)45–54
   PubMedGoogle Scholar
• Anton LC, Ruiz S, Barrio E, Marques G, Sanchez A, Vivanco F. C3 binds with similar efficiency to Fab and Fc regions of IgG immune aggregates. Eur J Immunol 1994; 24(3)599–604
   PubMedGoogle Scholar
• Walport MJ, Davies KA. Complement and immune complexes. Res Immunol 1996; 147(2)103–109
   PubMedGoogle Scholar
• Hebert LA. The clearance of immune complexes from the circulation of man and other primates. Am J Kidney Dis 1991; 17(3)352–361
   PubMedGoogle Scholar
• Anderson CL. Human IgG Fc receptors. Clin Immunol Immunopathol 1989; 53(2 Pt 2)S63–S71
   Google Scholar
• Gorgani NN, Parish CR, Altin JG. Differential binding of histidine-rich glycoprotein (HRG) to human IgG subclasses and IgG molecules containing kappa and lambda light chains. J Biol Chem 1999; 274(42)29633–29640
   PubMedGoogle Scholar
• Gorgani NN, Altin JG, Parish CR. Histidine-rich glycoprotein regulates the binding of monomeric IgG and immune complexes to monocytes. Int Immunol 1999; 11(8)1275–1282
   PubMedGoogle Scholar
• Gorgani NN, Altin JG, Parish CR. Histidine-rich glycoprotein prevents the formation of insoluble immune complexes by rheumatoid factor. Immunology 1999; 98(3)456–463
   PubMedGoogle Scholar
• Hulett MD, Hogarth PM. Molecular basis of Fc receptor function. Adv Immunol 1994; 57: 1–127
   PubMed Web of Science ®Google Scholar
• Zack DJ, Stempniak M, Wong AL, Weisbart RH. Localization of an Fc-binding reactivity to the constant region of human IgG4. Implications for the pathogenesis of rheumatoid arthritis. J Immunol 1995; 155(10)5057–5063
   PubMed Web of Science ®Google Scholar
• Shlomchik MJ, Euler CW, Christensen SC, William J. Activation of rheumatoid factor (RF) B cells and somatic hypermutation outside of germinal centers in autoimmune-prone MRL/lpr mice. Ann N Y Acad Sci USA 2003; 987: 38–50
   PubMedGoogle Scholar
• Lorenz HM, Herrmann M, Winkler T, Gaipl U, Kalden JR. Role of apoptosis in autoimmunity. Apoptosis 2000; 5(5)443–449
   PubMed Web of Science ®Google Scholar
• Yasutomo K. Pathological lymphocyte activation by defective clearance of self-ligands in systemic lupus erythematosus. Rheumatology (Oxford) 2003; 42(2)214–222
   PubMedGoogle Scholar
• Mountz JD, Wu J, Cheng J, Zhou T. Autoimmune disease. A problem of defective apoptosis. Arthritis Rheum 1994; 37(10)1415–1420
   PubMedGoogle Scholar
• Savill J. Apoptosis. Phagocytic docking without shocking. Nature 1998; 392(6675)442–443
   PubMed Web of Science ®Google Scholar
• Fadok VA. Clearance: The last and often forgotten stage of apoptosis. J Mammary Gland Biol Neoplasia 1999; 4(2)203–211
   PubMedGoogle Scholar
• Luciani MF, Chimini G. The ATP binding cassette transporter ABC1, is required for the engulfment of corpses generated by apoptotic cell death. Embo J 1996; 15(2)226–235
   PubMedGoogle Scholar
• Wu YC, Horvitz HR. C. elegans phagocytosis and cell-migration protein CED-5 is similar to human DOCK180. Nature 1998; 392(6675)501–504
   PubMed Web of Science ®Google Scholar
• Leverrier Y, Lorenzi R, Blundell MP, Brickell P, Kinnon C, Ridley AJ, Thrasher AJ. Cutting edge: The Wiskott–Aldrich syndrome protein is required for efficient phagocytosis of apoptotic cells. J Immunol 2001; 166(8)4831–4834
   PubMedGoogle Scholar
• Gershov D, Kim S, Brot N, Elkon KB. C-Reeactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: Implications for systemic autoimmunity. J Exp Med 2000; 192(9)1353–1364
   PubMed Web of Science ®Google Scholar
• Kao KJ, Klein PA. A monoclonal antibody-based enzyme-linked immunosorbent assay for quantitation of plasma thrombospondin. Am J Clin Pathol 1986; 86(3)317–323
   PubMedGoogle Scholar
• Savill J, Hogg N, Ren Y, Haslett C. Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis. J Clin Invest 1992; 90(4)1513–1522
   PubMed Web of Science ®Google Scholar
• Gorgani NN, Smith BA, Kono DH, Theofilopoulos AN. Histidine-rich glycoprotein binds to DNA and Fc gamma RI and potentiates the ingestion of apoptotic cells by macrophages. J Immunol 2002; 169(9)4745–4751
   PubMedGoogle Scholar
• Jones AL, Poon IK, Hulett MD, Parish CR. Histidine-rich glycoprotein specifically binds to necrotic cells via its amino-terminal domain and facilitates necrotic cell phagocytosis. J Biol Chem 2005; 280(42)35733–35741
   PubMedGoogle Scholar
• Wu D, Ingram A, Lahti JH, Mazza B, Grenet J, Kapoor A, Liu L, Kidd VJ, Tang D. Apoptotic release of histones from nucleosomes. J Biol Chem 2002; 277(14)12001–12008
   PubMedGoogle Scholar
• Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994; 179(4)1317–1330
   PubMed Web of Science ®Google Scholar
• Scott RS, McMahon EJ, Pop SM, Reap EA, Caricchio R, Cohen PL, Earp HS, Matsushima GK. Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature 2001; 411(6834)207–211
   PubMed Web of Science ®Google Scholar
• Ronnblom L, Alm GV. An etiopathogenic role for the type I IFN system in SLE. Trends Immunol 2001; 22(8)427–431
   PubMed Web of Science ®Google Scholar
• Ronnblom L, Eloranta ML, Alm GV. Role of natural interferon-alpha producing cells (plasmacytoid dendritic cells) in autoimmunity. Autoimmunity 2003; 36(8)463–472
   PubMed Web of Science ®Google Scholar
• Lau CM, Broughton C, Tabor AS, Akira S, Flavell RA, Mamula MJ, Christensen SR, Shlomchik MJ, Viglianti GA, Rifkin IR. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/toll-like receptor 7 engagement. J Exp Med 2005; 202(9)1171–1177
   PubMed Web of Science ®Google Scholar
• Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and toll-like receptors. Nature 2002; 416(6881)603–607
   PubMed Web of Science ®Google Scholar
• Rifkin IR, Leadbetter EA, Busconi L, Viglianti G, Marshak-Rothstein A. Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev 2005; 204: 27–42
   PubMed Web of Science ®Google Scholar
• Viglianti GA, Lau CM, Hanley TM, Miko BA, Shlomchik MJ, Marshak-Rothstein A. Activation of autoreactive B cells by CpG dsDNA. Immunity 2003; 19(6)837–847
   PubMed Web of Science ®Google Scholar
• Banchereau J, Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006; 25(3)383–392
   PubMed Web of Science ®Google Scholar
• Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005; 23: 307–336
   PubMed Web of Science ®Google Scholar
• Leber PaM R. Immune complex disease. The inflammatory process2nd ed., B Zweifach, R McCluskey. Acamedic Press, NY 1974; 3: 401–438
   Google Scholar
• Theofilopoulos AN, Dixon FJ. Immune complexes in human diseases: A review. Am J Pathol 1980; 100(2)529–594
   PubMedGoogle Scholar
• Schifferli JA. Complement and immune complexes. Res Immunol 1996; 147(2)109–110
   PubMedGoogle Scholar
• Hebert LA, Cosio FG, Birmingham DJ. Complement and complement regulatory proteins in renal disease. Immunological renal diseases. Lippincott-Raven publishers, Philadelphia 1997; 377–395
   Google Scholar
• Theofilopoulos AN. Evaluation and clinical significance of circulating immune complexes. Prog Clin Immunol 1980; 4: 63–106
   PubMedGoogle Scholar
• Wener MH, Mannik M. Mechanisms of immune deposit formation in renal glomeruli. Springer Semin Immunopathol 1986; 9(2–3)219–235
   PubMedGoogle Scholar
• Haakenstad AO, Striker GE, Mannik M. The glomerular deposition of soluble immune complexes prepared with reduced and alkylated antibodies and with intact antibodies in mice. Lab Invest 1976; 35(3)293–301
   PubMedGoogle Scholar